Nasal Polyp Score [ Time Frame: Baseline to Week 52 ]
Change from baseline in total Nasal Polyp Score at Week 52. The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy.
Participant Reported Nasal Congestion [ Time Frame: Baseline to Week 52 ]
Change from baseline in Nasal Congestion score evaluated as part of the Nasal Polyposis Symptom Diary at Week 52. Nasal Congestion Score is captured by asking participants to rate the severity of their worst nasal congestion over the past 24 hours (0-None; 1-Mild; 2-Moderate; 3-Severe).
Secondary Outcome Measures
Nasal Polyp Score [ Time Frame: Baseline to Week 24 ]
Press release content from PR Newswire. The AP news staff was not involved in its creation.
American Lung Association to Reduce Asthma-related ER and Hospital Visits for Communities Most Burdened by Asthma
April 8, 2021 GMT
American Lung Association logo (PRNewsfoto/American Lung Association)
CHICAGO, April 8, 2021 /PRNewswire/ In the U.S., 24.8 million people are living with asthma, including 5.5 million children. Without proper management of the disease, asthma symptoms can worsen and result in asthma attacks, emergency department and hospital visits. While asthma affects all people, the burden is not shared equally, with children and low-income individuals most likely to have asthma and suffer from severe asthma attacks, hospitalization and even death. Asthma morbidity and mortality also disproportionately affects Black and Hispanic individuals. In an effort to improve health and prevent asthma-related emergency department and hospital visits, especially for those most impac
New Medication Reduces Asthma Exacerbations and Improves Lung Function in Patients with Severe, Uncontrolled Asthma
Share Article
Results from the phase 3 NAVIGATOR study was presented during the 2021 AAAAI Virtual Annual Meeting. Tezepelumab has the potential to transform treatment for a broad population of patients with severe asthma irrespective of their type of inflammation, including those with and without an eosinophilic phenotype.” MILWAUKEE (PRWEB) February 26, 2021 Tezepelumab, a human monoclonal antibody, was found to be effective for patients with severe uncontrolled asthma in a phase 3 trial funded by AstraZeneca and Amgen, Inc. Data from the abstract was presented during the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting.